Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paliperidone palmitate (II) injection replacing oral antipsychotics in schizophrenia
ChiCTR2600124217Phase 4Not yet recruiting
- Sponsor
- Affiliated Brain Hospital of Nanjing Medical University
- Start
- May 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of paliperidone palmitate in schizophrenia, sponsored by Affiliated Brain Hospital of Nanjing Medical University. Primary endpoint: Positive and Negative Symptoms. Planned start May 2026; status: not yet recruiting.
02
Drugs
paliperidone palmitate
03
Conditions
schizophrenia
Beyond the preview
Go deeper on ChiCTR2600124217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600124217.